Safety and Efficacy of the Use of pdVWF/FVIII-C in Patients with von Willebrand Disease: A Prospective, Observational, Post-Authorization Study

Introduction Plasma-derived von Willebrand factor containing FVIII concentrates (pdVWF/FVIII-C) are indicated as replacement therapy for patients with von Willebrand disease (VWD). This study assessed safety and efficacy associated with long-term real-world experience of the pdVWF/FVIII-C, Fanhdi ®...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Olga Benítez Hidalgo MD, Cristina Marzo Alonso MD, MSc, Francisco José López Jaime MD, Marina Carrasco MD, Maria del Mar Nieto Hernández MD, Natalia Afonso BPharm, Alejhandra Lei MD, Dermot Whyms MSc, Kim Hanna MSc, Maria Esperança Aragonés MSc, Mireia Torres MSc, Juan Oliveras PharmD
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	SAGE Publishing 2025-03-01
Cyfres:	Clinical and Applied Thrombosis/Hemostasis
Mynediad Ar-lein:	https://doi.org/10.1177/10760296251327593
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!